We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.
We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.
We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.
We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.
We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.
We are studying a combination of cetuximab and chemotherapy followed by immunotherapy for patients with recurrent or metastatic head and neck cancer. The goal is to see if this treatment improves survival and response rates for those with a specific PD-L1 score.
We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.
We are studying whether hormone therapy and a guided online sleep program can help improve sleep and mood in perimenopausal women. This trial aims to enhance mental health and overall well-being during this transition.
We are studying an oral treatment with living bacteria for people with diarrhea-predominant irritable bowel syndrome (IBS-D). The goal is to see if it helps reduce symptoms compared to a placebo.
We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.
We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.
We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.
We are investigating whether a medication can improve thinking and movement tasks in elderly volunteers. This study compares the effects of donepezil to a placebo on brain activity and performance.
We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.
We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.
We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.
We are studying a new bispecific antibody, MCLA-128, in patients with solid tumors that have an NRG1 fusion. The goal is to evaluate its safety and how well it may work against these tumors.
We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.
We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.
We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.